Ocuphire Pharma Investor Updates slide image

Ocuphire Pharma Investor Updates

P CO 6 Potential 'Best in Class' Presbyopia Drop Topline Results From Vega-1 Were Positive... Nyxol + LDP Presbyopia Treatment is Differentiated: Statistically significant efficacy data ✓ Favorable safety profile ✓ Comfort and tolerability ✓ Fast onset ✔ Long duration ✓ Maintain good distance visual acuity (night/day) ✓ Novel tunable pupil modulation Ocuphire PHARMA
View entire presentation